Huashi Baidu Granule in the Treatment of Pediatric Patients With Mild Coronavirus Disease 2019

• Status: Completed
• Trial end date: 2022-06-30
• Target enrollment: 0
• Participant gender: All

Summary

The investigators conducted a single-center, open-label, parallel-group randomized controlled trial to assess the efficacy and safety of a Chinese herb compound granule Huashi Baidu granule (HSBDG) in pediatric patients with laboratory-confirmed mild COVID-19. 108 recruited children (aged 3 to 18 years) with laboratory-confirmed mild COVID-19 were randomly allocated 2:1 to receive oral HSBDG for 5 consecutive days (intervention group) and to receive compound pholcodine oral solution for 5 consecutive days (control group). The negative conversion time of SARS-CoV-2 nucleic acid and symptom scores were recorded.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Shanghai Children's Medical Center
• Treatments: Pholcodine

Criteria

Inclusion Criteria:

• attend the COVID-19 Fangcang Shelter Hospitals in Shanghai, China

• with laboratory-confirmed COVID-19

• compliance with the diagnostic criteria for mild COVID-19

• age 3 to 18 years.

Exclusion Criteria:

• with underlying disease(s) such as chronic pulmonary disease, immunodeficiency, tumors, etc.,

• allergy or intolerance to taking Chinese medicine herbs or compound pholcodine oral solution

• with poor compliance (defined as inability to comply with the protocol)

• decline to participate